PMEF
TVRD

Point72 Middle East FZE’s Tvardi Therapeutics TVRD Stock Holding History

Point72 Middle East FZE’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-111
Closed -$6.74K – 1943
2023
Q3 		$6.74K Sell
111
-1,439
-93% -$135K ﹤0.01% 1363
2023
Q2 		$158K Buy
1,550
+1,200
+343% +$165K ﹤0.01% 1121
2023
Q1 		$62K Buy
+350
New +$117K ﹤0.01% 1224

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Middle East FZE's TVRD Position: Q4 2023 in Review

Point72 Middle East FZE sold out of Tvardi Therapeutics (TVRD) in Q4 2023, closing a stake of 111 shares — an estimated $6.74K sold.

Point72 Middle East FZE first reported a position in TVRD in Q1 2023 and held it in 3 quarters. The position peaked at $158K in Q2 2023. 109 funds tracked by Wall St. Rank hold TVRD as of Q4 2023.

  • Point72 Middle East FZE reported no remaining Tvardi Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 111 Tvardi Therapeutics shares in Q4 2023, an estimated $6.74K.
  • Point72 Middle East FZE first reported a position in Tvardi Therapeutics in Q1 2023 and held it in 3 quarters.
  • Point72 Middle East FZE's Tvardi Therapeutics position peaked at $158K in Q2 2023.
  • 109 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.